Glenmark bags USFDA nod for Arformoterol Tartrate Inhalation Solution

Mumbai: Drugmaker, Glenmark Pharmaceuticals Ltd, today announced that the company has received final approval from the United States Food & Drug Administration (USFDA) for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials.

The product is a generic version of BROVANA Inhalation Solution, 15 mcg/2 mL, of Sunovion Pharmaceuticals Inc.

Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company's North American manufacturing facility based in Monroe, North Carolina, and marks the company's first nebulizer approval.

Commenting on the launch, Sanjeev Krishan, President, Glenmark North America said, "We are very excited to be one of the first generic companies to receive approval for such an important product for our customers. This also marks our third approval from our state-of-the art manufacturing facility in Monroe in 2021, demonstrating our capability to offer high quality medicines with affordable access across multiple dosage platforms."

According to IQVIA sales data for the 12 month period ending April 2021, the BROVANA Inhalation Solution, 15 mcg/2 mL market achieved annual sales of approximately $437.9 million*.

Glenmark's current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA's pending approval with the USFDA.

Read also: Glenmark gets CDSCO panel nod to revise phase 4 protocol for Minocycline Hydrochloride Topical Gel